Concepedia

Publication | Open Access

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

DOIFull Paper Access

97

Citations

32

References

2012

Year

Christoph Renner, Pier Luigi Zinzani, Rémy Gressin, Dirk Klingbiel, Pierre‐Yves Dietrich, Felicitas Hitz, Mario Bargetzi, Walter Mingrone, G. Martinelli, Andreas Trojan,
Haematologica

Abstract

Everolimus as a single agent is well tolerated and has anti-lymphoma activity in relapsed or refractory mantle cell lymphoma. Further studies of everolimus in combination with chemotherapy or as a single agent for maintenance treatment are warranted.

References

YearCitations

Page 1